(原标题:【券商聚焦】西部证券维持和誉-B(02256)“买入”评级 指匹米替尼开启全球商业化)金吾财讯|西部证券发布研报指,和誉-B(02256.HK)核心产品匹米替尼(贝捷迈?)获NMPA批准上市,成为中国首个自主研发的腱鞘巨细胞瘤系统性治疗药物,其全球商业化权益由默克负责。KRAS G12D抑制剂ABSK141同步获中美临床试验批准,口服PD-L1抑制剂ABSK043联合EGFR-TKI治疗...
Source Link(原标题:【券商聚焦】西部证券维持和誉-B(02256)“买入”评级 指匹米替尼开启全球商业化)金吾财讯|西部证券发布研报指,和誉-B(02256.HK)核心产品匹米替尼(贝捷迈?)获NMPA批准上市,成为中国首个自主研发的腱鞘巨细胞瘤系统性治疗药物,其全球商业化权益由默克负责。KRAS G12D抑制剂ABSK141同步获中美临床试验批准,口服PD-L1抑制剂ABSK043联合EGFR-TKI治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.